GlassScriptPhysician profile
Son B Mai
NPI 1174136071
$1,940.23
in general payments reported to CMS, 2019-2025
18 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $537 · 2023: $563 · 2024: $212 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.06 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.52 | 2021-2025 | |
| Novo Nordisk INC | $299.56 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $160.07 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $122.77 | 2022-2024 | |
| Astellas Pharma US INC | $122.05 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $109.95 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $105.89 | 2021-2023 | Rexulti |
| Amgen INC. | $104.54 | 2024-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $84.41 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $79.34 | 2022-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $78.40 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $63.90 | 2022 | |
| Xeris Pharmaceuticals, INC. | $44.48 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $41.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.36 | 2021-2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $35.74 | 2025 | Tymlos |
| Amarin Pharma, INC. | $24.13 | 2021 | |
| Gilead Sciences, INC. | $23.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.